Gastro Medical News about Esophageal cancer

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer
Diseases of the Esophagus, 08/20/08

Cho SH et al. - In a trial to evaluate the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer, it was shown that the main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer

Methods

Pts with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks
Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy
After concurrent chemoradiotherapy, additive chemotherapy was repeated up to 6 cycles

Results

30 pts were enrolled; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20, including 5 complete pathologic responses in primary lesions
Improvement of dysphagia was seen in 21 pts
In pts with stage II or III esophageal cancer, median progression-free survival and overall survival were 10.6 months, respectively
In pts with stage IV esophageal cancer, median progression-free survival and overall survival were 5.4 months and 11.6 months, respectively

<< Previous
Lack of Correlation Between Serum Anti-HBcore Detectability and...

Next >>
Presentation and management of late-onset duodenomegaly in a...